PICASSO™: A Human-First Framework for Federally Mandated New Approach Methodologies

The bridge to humans is where drug discovery collapses. New Approach Methodologies (NAMs), powered by organoids, microphysiological systems, and AI/ML, are emerging as the foundation of a human-first drug discovery paradigm. Yet without standards, most NAMs remain fragmented, irreproducible, and detached from Phase 3–level rigor: diversity, reproducibility, and clinically anchored endpoints. PICASSO™ (Phenotype-Informed Clinical Abstraction for Systematic Simulation and Outcomes) closes this gap by algorithmically anchoring NAMs to large, diverse patient cohorts. By abstracting only the essential disease-driving features that align with clinical outcomes, PICASSO™ strips away irrelevant complexity while enforcing reproducibility and clinical fidelity. Rather than replacing animal models, it redeploys them strategically when they reflect human disease mechanisms, sharpening their translational value. Compact in scale yet anchored to Phase 3–sized populations, NAMs operating within PICASSO™ become standardized, scalable, and capable of outcome-level predictions with regulatory-grade confidence. PICASSO™ is inclusive but discerning, transforming NAMs—whether algorithmic, human, or animal — from boutique pilot tools into engines for discovery, trial design, and precision therapeutics, ushering in a truly human-centered biomedical future that passes the “humanness” test.